Management & Regulatory

How Is Esteve's Expansion Shaping the Global Pharmaceutical Industry?
Management & Regulatory How Is Esteve's Expansion Shaping the Global Pharmaceutical Industry?

The global pharmaceutical industry is undergoing a transformative phase, driven by rapid advancements in technology, increasing demand for healthcare solutions, and strategic expansions by leading companies. Esteve Pharmaceuticals, a major player in the sector, is making headlines with its

Is the Biotech Industry in 2024 Thriving or Struggling with Layoffs?
Management & Regulatory Is the Biotech Industry in 2024 Thriving or Struggling with Layoffs?

The biotech industry in 2024 presents a stark contrast. On one hand, a surge of startups is enjoying robust financial support and offering abundant job opportunities. On the other hand, major established companies are grappling with significant layoffs and restructuring efforts. This juxtaposition

Sutro Biopharma Inc Faces Significant Stock Volatility and Revenue Decline
Management & Regulatory Sutro Biopharma Inc Faces Significant Stock Volatility and Revenue Decline

Sutro Biopharma Inc. (NASDAQ:STRO) has been experiencing a challenging period, marked by considerable stock price fluctuations and substantial revenue declines. This California-based biotech firm, specializing in oncology therapeutics, is grappling with mixed sentiments among investors amidst a

FDA Modernizes Drug Evaluation to Boost Efficiency and Effectiveness
Management & Regulatory FDA Modernizes Drug Evaluation to Boost Efficiency and Effectiveness

The FDA's Center for Drug Evaluation and Research (CDER) has embarked on a robust modernization initiative to transform its New Drug Regulatory Program (NDRP). Launched in 2017, this comprehensive effort aims to enhance the efficiency and effectiveness of CDER processes in response to

FDA Advances CDER's New Drug Regulatory Program with Modernization Steps
Management & Regulatory FDA Advances CDER's New Drug Regulatory Program with Modernization Steps

The FDA's New Drug Regulatory Program (NDRP) within the Center for Drug Evaluation and Research (CDER) has undergone substantial modernization efforts since its launch in 2017. Aimed at enhancing the efficiency and effectiveness of CDER processes in light of advances in genetic science,

Veranova Invests $30M in Devens Facility to Expand ADC Capabilities
Management & Regulatory Veranova Invests $30M in Devens Facility to Expand ADC Capabilities

In a significant move within the pharmaceutical manufacturing industry, Veranova has announced a substantial $30 million investment to enhance its Devens, Massachusetts facility. This strategic expansion is designed to bolster Veranova’s capabilities in developing and manufacturing antibody-drug

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later